The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer

Afatinib is a second generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) characterized as an irreversible pan-human EGFR (HER) family inhibitor. Afatinib remains effective for a subpopulation of patients with non-small cell lung cancer (NSCLC) with acquired resistance to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yonesaka, Kimio, Kudo, Keita, Nishida, Satomi, Takahama, Takayuki, Iwasa, Tsutomu, Yoshida, Takeshi, Tanaka, Kaoru, Takeda, Masayuki, Kaneda, Hiroyasu, Okamoto, Isamu, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741788/
https://www.ncbi.nlm.nih.gov/pubmed/26418897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741788/
https://www.ncbi.nlm.nih.gov/pubmed/26418897

Ejemplares similares